What is the official website of Pharmacyclics, an AbbVie Company ?

The official website of Pharmacyclics, an AbbVie Company is http://www.pharmacyclics.com.

What is Pharmacyclics, an AbbVie Company's cybersecurity risk score?

Pharmacyclics, an AbbVie Company has an AI-generated cybersecurity risk score of 756 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Pharmacyclics, an AbbVie Company experienced?

According to Rankiteo, Pharmacyclics, an AbbVie Company currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Pharmacyclics, an AbbVie Company been affected by any supply chain cyber incidents ?

According to Rankiteo, Pharmacyclics, an AbbVie Company has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Pharmacyclics, an AbbVie Company have SOC 2 Type 1 certification ?

According to Rankiteo, Pharmacyclics, an AbbVie Company is not certified under SOC 2 Type 1.

Does Pharmacyclics, an AbbVie Company have SOC 2 Type 2 certification ?

According to Rankiteo, Pharmacyclics, an AbbVie Company does not hold a SOC 2 Type 2 certification.

Does Pharmacyclics, an AbbVie Company comply with GDPR ?

According to Rankiteo, Pharmacyclics, an AbbVie Company is not listed as GDPR compliant.

Does Pharmacyclics, an AbbVie Company have PCI DSS certification ?

According to Rankiteo, Pharmacyclics, an AbbVie Company does not currently maintain PCI DSS compliance.

Does Pharmacyclics, an AbbVie Company comply with HIPAA ?

According to Rankiteo, Pharmacyclics, an AbbVie Company is not compliant with HIPAA regulations.

Does Pharmacyclics, an AbbVie Company have ISO 27001 certification ?

According to Rankiteo,Pharmacyclics, an AbbVie Company is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Pharmacyclics, an AbbVie Company operate in ?

Pharmacyclics, an AbbVie Company operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Pharmacyclics, an AbbVie Company have ?

Pharmacyclics, an AbbVie Company employs approximately 613 people worldwide.

Does Pharmacyclics, an AbbVie Company own any subsidiaries ?

Pharmacyclics, an AbbVie Company presently has no subsidiaries across any sectors.

How many LinkedIn followers does Pharmacyclics, an AbbVie Company have ?

Pharmacyclics, an AbbVie Company's official LinkedIn profile has approximately 29,678 followers.

What is the NAICS classification code for Pharmacyclics, an AbbVie Company ?

Pharmacyclics, an AbbVie Company is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Pharmacyclics, an AbbVie Company have a Crunchbase profile ?

Yes, Pharmacyclics, an AbbVie Company has an official profile on Crunchbase, which can be accessed here: https://www.crunchbase.com/organization/pharmacyclics.

Does Pharmacyclics, an AbbVie Company have a LinkedIn profile ?

Yes, Pharmacyclics, an AbbVie Company maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/pharmacyclics.

How many cybersecurity incidents has Pharmacyclics, an AbbVie Company experienced ?

As of September 22, 2026, Rankiteo reports that Pharmacyclics, an AbbVie Company has not experienced any cybersecurity incidents.

How many peer or competitor companies does Pharmacyclics, an AbbVie Company have ?

Pharmacyclics, an AbbVie Company has an estimated 5,770 peer or competitor companies worldwide.

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

PAC

Boost Score +25 with badge (5 left)

756

/1000

Fair

781

/1000

Fair

Pharmacyclics, an AbbVie Company Vendor Cyber Rating & Cyber Score

pharmacyclics.com

cb in

Add Your Compliance Badge

Pharmacyclics is committed to the development and commercialization of novel therapies intended to improve the quality and duration of life and to resolve serious unmet medical needs for cancer patients. Pharmacyclics is a wholly-owned subsidiary of AbbVie (NYSE:ABBV), a global, research-based biopharmaceutical company. Oncology is a key therapeutic area for AbbVie, with a portfolio consisting of three marketed products and a pipeline containing multiple promising new molecules that are being studied in more than 200 clinical trials for over 20 different types of cancer. More than 1,200 Pharmacyclics and AbbVie research scientists, clinicians, marketing, operations and corporate professionals work in the San Francisco Bay Area. They

PAC

Pharmacyclics, an AbbVie Company CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

PAC Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for PAC

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Pharmacyclics, an AbbVie Company in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Pharmacyclics, an AbbVie Company in 2026.

Incident Types PAC vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Pharmacyclics, an AbbVie Company in 2026.

Incident History - PAC (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Pharmacyclics, an AbbVie Company Subsidiaries

Parent Company

PAC

Pharmaceutical Manufacturing

Website: http://www.pharmacyclics.com

Company Size: 613

No subsidiary data available for this company.

Loading…

Pharmacyclics, an AbbVie Company Similar Companies

Johnson & Johnson Innovative Medicine

jnj.com

At Johnson & Johnson Innovative Medicine, we innovate with purpose, to lead where medicine is going. The experiences of patients around the world inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science with compassion, we confidently address the most complex diseases of our time and develop the potential medicines of tomorrow. We are continuously working to develop treatments, aspiring to find cures, pioneering the path from lab to life, and championing patients every step of the way. https://bit.ly/3reuMvK

Dr. Reddy's Laboratories

drreddys.com

Established in 1984, we are a global pharmaceutical company headquartered in Hyderabad, India. Driven by our purpose of ‘Good Health Can’t Wait’, we work to provide access to affordable and innovative medicines. We offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major markets include USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in future growth drivers such as access to novel molecules, digital therapeutics and consumer healthcare. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com. Caution Notice: Dr. Reddy's has been made aware of candidates receiving fraudulent job opportunities from unauthorised recruiting agencies or people impersonating Dr. Reddy's leaders. These fraudulent jobs may be advertised on employment sites or mimic our careers site and company email addresses. Please know that Dr. Reddy's Laboratories has no affiliation or connection to these situations. Dr. Reddy's (and its associated/group companies) follows a formal recruitment process through its own HR department. Please report immediately in case you suspect a fraudulent job. You may raise your concern by: Accessing https://drreddys.ethicspoint.com. Calling on the hotline number. List of hotline numbers are available in https://drreddys.ethicspoint.com. The hotline is available 24x7 in multiple languages. Writing to [email protected] or [email protected]. For our community guidelines on LinkedIn, please visit: https://shorturl.at/LTvNZ

Novo Nordisk

cb novonordisk.com

We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Founded in Denmark in 1923, today we employ more than 68,800 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases. Want to learn more? Visit www.novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to block and remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html

Servier

servier.com

Founded to serve health 70 years ago, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a sustainable world. The Group’s unique governance model preserves its independence and means it can fully serve its vocation of being committed to therapeutic progress to serve patient needs while adopting a long-term vision. Its employees are fully committed to this shared vocation, which serves as a source of inspiration every day. A world leader in cardiometabolism and venous diseases, Servier has made a major shift into oncology, which represents a new pillar of strategic growth. The Group devotes close to 70% of its R&D budget to this field, with the ambition of becoming a focused and innovative player in the development of treatments targeting rare cancers. Neurology will constitute a future growth driver. Servier is focusing on a limited number of diseases in this area where accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote widespread access to quality care at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France, and Eastern Europe. In all these areas, the Group takes patient considerations into account at every stage of the medicine life cycle. Headquartered in France, Servier relies on committed teams and strong geographical footprint; its medicines are available in close to 140 countries. In 2023/2024, the Group achieved sales revenue of €5.9 billion and EBITDA of €1.3 billion in 2024 (22.2%). Today, the Group employs over 22,000 people worldwide. -- To report a suspected adverse event with a Servier drug, please visit servier.com

AUROBINDO PHARMA LTD

aurobindo.com

Aurobindo Pharma Limited (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and markets a wide range of generic pharmaceuticals, branded specialty drugs, and active pharmaceutical ingredients (APIs) across more than 150 countries. It is ranked among the top 10 generic companies in eight European nations and holds the distinction of being the largest generic pharmaceutical company in the United States. With over 30 state-of-the-art manufacturing and packaging facilities approved by leading global regulatory authorities including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, and Brazil ANVISA, Aurobindo Pharma ensures the highest standards of quality. Its robust portfolio spans eight major therapeutic areas: Central Nervous System (CNS), Antiretroviral (ARV), Cardiovascular (CVS), Antibiotics, Gastroenterology, Anti-diabetics, Oncology, and Dermatology, supported by a strong R&D infrastructure that drives innovation, affordability, and accessibility.

Eli Lilly and Company

lilly.com

We're a medicine company turning science into healing to make life better for people around the world. It all started nearly 150 years ago with a clear vision from founder Colonel Eli Lilly: "Take what you find here and make it better and better." Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing science to solve some of the world's most significant health challenges. General Information and Guidelines: When you engage with us on LinkedIn, you're agreeing to these Community Guidelines: https://e.lilly/guidelines. If you have questions about a Lilly medicine, contact The Lilly Answers Center at 1-800-Lilly-Rx (1-800-545-5979) Monday through Friday, excluding company holidays.

Merck

merck.us

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com. This site is intended for residents of the United States and Canada and their territories only. FLS: http://merck.us/3TKXNuZ

AbbVie

cb abbvie.com

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.

Cipla

cipla.com

Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935. A compassionate approach to healthcare that goes beyond the pursuit of profit and growth has been the force impelling Cipla’s history over the years. Our credo and our purpose of ‘Caring for Life' continues to guide our actions towards our people and the planet for creating a sustainable future. Cipla today has presence in 80+ countries, providing over 1,500 products across various therapeutic categories in 50+ dosage forms. Keeping with our legacy of care, we constantly strive to ensure access to high-quality medicines that make a difference in the lives of patients. Our paradigm-changing offer of a triple anti-retroviral (ARV) therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 was pivotal in bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. An unmatched presence across the care continuum (awareness, prevention, diagnosis, treatment and adherence) and the widest range of drug-device combinations has established Cipla’s respiratory leadership in India and other key emerging markets. Armed with this legacy and a deep understanding of the lungs, we have articulated our aspiration to become a global lung leader and help millions breathe free.

Loading…

NEWS

Pharmacyclics, an AbbVie Company CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

March 05, 2015 08:00 AM

AbbVie boosts cancer drug pipeline with $21 billion Pharmacyclics deal

AbbVie Inc is to buy Pharmacyclics Inc for about $21 billion, giving it access to what is expected to be one of the world's top-selling cancer drugs.

Read Article

March 05, 2015 08:00 AM

AbbVie to Buy Pharmacyclics in $21 Billion Deal

AbbVie Inc. ABBV -0.19%decrease; red down pointing triangle said late Wednesday it will buy cancer biotech Pharmacyclics Inc. in a $21...

Read Article

March 05, 2015 08:00 AM

AbbVie’s $21 billion deal for Pharmacyclics — a sign of ‘desperation’?

AbbVie was willing to pay up to get its hands on a drug and its skyrocketing sales. Is this a sign of 'desperation.'

Read Article

March 05, 2015 08:00 AM

Billionaire Robert Duggan's Bet On Pharmacyclics Stands Among Top Trades Of Crisis Era

Add Pharmacyclics CEO Robert Duggan to the list of billionaires who made audacious bets during the market tumult and held on to only to see...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-94426

SUMMARY

A vulnerability was determined in xuxueli xxl-job up to 3.5.0. The impacted element is an unknown function of the file /jobgroup/insert. This manipulation of the argument Name causes cross site scripting. The attack can be initiated remotely. The exploit has been publicly disclosed and may be utilized. The vendor was contacted early about this disclosure but did not respond in any way.

Published

Date2026-09-21

Updated

Date2026-09-21

RISK INFORMATION (Score: 3.5)

cvss2

Base Score: 4.0

Complexity: LOW

AV:N/AC:L/Au:S/C:N/I:P/A:N

cvss3

Base Score: 3.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:R/S:U/C:N/I:L/A:N

cvss4

Base Score: 2.0

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:P/VC:N/VI:L/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

1.4

Exploitability

2.1

REFERENCES

CVE-2026-94425

SUMMARY

A vulnerability was found in Moore Threads MTT S80 Driver Package 340.150. The affected element is the function sub_140006F0C in the library mtdispkm64.sys of the component IOCTL Handler. The manipulation results in improper privilege management. Attacking locally is a requirement. The vendor was contacted early about this disclosure but did not respond in any way.

Published

Date2026-09-21

Updated

Date2026-09-21

RISK INFORMATION (Score: 8.8)

cvss2

Base Score: 6.8

Complexity: LOW

AV:L/AC:L/Au:S/C:C/I:C/A:C

cvss3

Base Score: 8.8

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:C/C:H/I:H/A:H

cvss4

Base Score: 9.3

Complexity: LOW

CVSS:4.0/AV:L/AC:L/AT:N/PR:L/UI:N/VC:H/VI:H/VA:H/SC:H/SI:H/SA:H/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-94627

SUMMARY

vLLM Mooncake connector through 0.29.0 fails to properly manage GPU KV cache block ownership when concurrent child requests share a single transfer ID in prefill/decode disaggregated deployments. Attackers can trigger GPU memory exhaustion by submitting completion requests with multiple prompts, causing orphaned KV cache blocks to accumulate until process restart and eventually preventing legitimate requests from executing.

Published

Date2026-09-21

Updated

Date2026-09-21

RISK INFORMATION (Score: 7.5)

cvss3

Base Score: 7.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H

cvss4

Base Score: 8.7

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.6

Exploitability

3.9

REFERENCES

CVE-2026-94626

SUMMARY

vLLM through 0.29.0 fails to validate the tp_size parameter in kv_transfer_params on OpenAI-compatible completion endpoints, allowing attackers to allocate unbounded memory. Attackers can supply arbitrary tp_size values in prefill/decode disaggregated deployments to exhaust memory and trigger kernel OOM-kill of the decode worker process.

Published

Date2026-09-21

Updated

Date2026-09-21

RISK INFORMATION (Score: 7.5)

cvss3

Base Score: 7.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H

cvss4

Base Score: 8.7

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.6

Exploitability

3.9

REFERENCES

CVE-2026-94625

SUMMARY

vLLM through 0.29.0 contains a resource exhaustion vulnerability in MooncakeConnector where rejected prefill requests create ownerless transfer placeholders that are never reclaimed. Attackers can send rejected requests to exhaust sender task pools, causing valid requests to be delayed by up to 480 seconds while health checks continue returning success.

Published

Date2026-09-21

Updated

Date2026-09-21

RISK INFORMATION (Score: 5.3)

cvss3

Base Score: 5.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:L

cvss4

Base Score: 6.9

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

1.4

Exploitability

3.9

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…

Badge your company to reduce your risk score and your cyber insurance costs!

Trusted by insurers. Chosen by leaders.

Pharmacyclics, an AbbVie Company Vendor Cyber Rating & Cyber Score

PAC A.I CyberSecurity Scoring

Pharmacyclics, an AbbVie Company CyberSecurity News & History

PAC Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for PAC

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types PAC vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - PAC (X = Date, Y = Severity)

Pharmacyclics, an AbbVie Company Subsidiaries

Parent Company

PAC

Pharmacyclics, an AbbVie Company Similar Companies

Johnson & Johnson Innovative Medicine

Dr. Reddy's Laboratories

Novo Nordisk

Servier

AUROBINDO PHARMA LTD

Eli Lilly and Company

Merck

AbbVie

Cipla

Pharmacyclics, an AbbVie Company CyberSecurity News

AbbVie boosts cancer drug pipeline with $21 billion Pharmacyclics deal

AbbVie to Buy Pharmacyclics in $21 Billion Deal

AbbVie’s $21 billion deal for Pharmacyclics — a sign of ‘desperation’?

Billionaire Robert Duggan's Bet On Pharmacyclics Stands Among Top Trades Of Crisis Era

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo

Pharmacyclics, an AbbVie Company CyberSecurity News & History

PAC Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for PAC

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types PAC vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - PAC (X = Date, Y = Severity)

Pharmacyclics, an AbbVie Company Subsidiaries

Parent Company

PAC

Pharmacyclics, an AbbVie Company Similar Companies

Johnson & Johnson Innovative Medicine

Dr. Reddy's Laboratories

Novo Nordisk

Servier

AUROBINDO PHARMA LTD

Eli Lilly and Company

Merck

AbbVie

Cipla

Pharmacyclics, an AbbVie Company CyberSecurity News

AbbVie boosts cancer drug pipeline with $21 billion Pharmacyclics deal

AbbVie to Buy Pharmacyclics in $21 Billion Deal

AbbVie’s $21 billion deal for Pharmacyclics — a sign of ‘desperation’?

Billionaire Robert Duggan's Bet On Pharmacyclics Stands Among Top Trades Of Crisis Era

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo